

Genomic RNA from Human Respiratory Syncytial Virus, A2001/3-12

Catalog No. NR-44227

For research use only. Not for use in humans.

Contributor:

Martin Moore, Ph.D., Department of Pediatrics, Emory University, Atlanta, Georgia, USA

Manufacturer:

BEI Resources

Product Description:

Genomic RNA was isolated from a preparation of cell lysate and supernatant from *Homo sapiens* carcinoma cells (HEp-2; ATCC® CCL-23™) infected with human respiratory syncytial virus, A2001/3-12.

Human respiratory syncytial virus (RSV), A2001/3-12 was isolated from a nasal wash from an infant with RSV bronchiolitis in Nashville, Tennessee on March 12, 2001.¹ A2001/3-12 is one of six clinical RSV isolates that recently were shown to induce variable disease severity, lung interleukin-13 (IL-13) levels, and gob-5 levels in BALB/cJ mice.^{2,3,4}

NR-44227 has been qualified for PCR applications by amplification of an approximately 900 nucleotide sequence. Recommended dilutions for successful RT-PCR amplification are indicated on the Certificate of Analysis for each lot.

Material Provided:

Each vial contains approximately 100 µL of viral genomic RNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA). The viral genomic RNA is in a background of cellular nucleic acid and carrier RNA. The vial should be centrifuged prior to opening.

Packaging/Storage:

NR-44227 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -60°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Genomic RNA from Human Respiratory Syncytial Virus, A2001/3-12, NR-44227.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Moore, M., Personal Communication.
2. Stokes, K. L., et al. “Differential Pathogenesis of Respiratory Syncytial Virus Clinical Isolates in BALB/c Mice.” J. Virol. 85 (2011): 5782-5793. PubMed: 21471228.
3. Nakanishi, A., et al. “Role of gob-5 in Mucus Overproduction and Airway Hyperresponsiveness in Asthma.” Proc. Natl. Acad. Sci. U.S.A. 98 (2001): 5175-5180. PubMed: 11296262.
4. Walter, D. M., et al. “Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity.” J. Immunol. 167 (2001): 4668-4675. PubMed: 11591797.

ATCC® is a trademark of the American Type Culture Collection.

